TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33554255

Group type: EXPERIMENTAL
Intervention: Driver ablation
Number of subjects: 124

Group type: COMPARATOR
Intervention: Conventional ablation
Number of subjects: 124
Study: 32559003

Group type: EXPERIMENTAL
Intervention: Xenograft A
Number of subjects: 16

Group type: COMPARATOR
Intervention: Xenograft B
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Both xenografts
Number of subjects: 16
Study: 34374330

Group type: EXPERIMENTAL
Intervention: Physiotherapy intervention (4 sessions per week for 4 weeks, totaling 16 sessions)
Number of subjects: 80
Study: 32907792

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention (LI) focused on physical activity
Number of subjects: 74

Group type: COMPARATOR
Intervention: Care as usual (CAU)
Number of subjects: 74
Study: 32014311

Group type: EXPERIMENTAL
Intervention: Test group with individualized protamine titration based on ACT measurements
Number of subjects: 138

Group type: COMPARATOR
Intervention: Control group with standard protamine infusion of 1.3 mg per 1 mg (100 U) of heparin
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 138
Study: 32205019

Group type: EXPERIMENTAL
Intervention: High-grade PI retrolisthesis
Number of subjects: 887

Group type: EXPERIMENTAL
Intervention: Low-grade PI retrolisthesis
Number of subjects: 887

Group type: COMPARATOR
Intervention: Control group (no lumbar spondylolisthesis)
Number of subjects: 887
Study: 34464242

Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol (Bud + Form; 400/12 µg BID)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Fluticasone/salmeterol (Flu + Salm; 250/50 µg BID)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Formoterol only (Form; 12 µg BID)
Number of subjects: 63
Study: 35638262

Group type: EXPERIMENTAL
Intervention: High-intensity interval training (HIIT)
Number of subjects: 0
Study: 34382504

Group type: EXPERIMENTAL
Intervention: MBF Child Safety Matters (CSM) curriculum
Number of subjects: 2414

Group type: COMPARATOR
Intervention: Wait-list control (no intervention)
Number of subjects: 2414
Study: 32711460

Group type: EXPERIMENTAL
Intervention: Primary care records
Number of subjects: 2811
Study: 36179772

Group type: EXPERIMENTAL
Intervention: Good adherence to OACs (PDC >80%)
Number of subjects: 778

Group type: EXPERIMENTAL
Intervention: Vitamin K antagonists (VKAs) among adherent patients
Number of subjects: 778

Group type: COMPARATOR
Intervention: Direct oral anticoagulants (DOACs) among adherent patients
Number of subjects: 778
Study: 33851966

Group type: EXPERIMENTAL
Intervention: NP202, 1000 mg, daily for 3 months
Number of subjects: 147

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: NP202
Number of subjects: 147
Study: 35534822

Group type: EXPERIMENTAL
Intervention: Intensified physiotherapy program (endurance and muscle force exercises using cycle ergometer)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control group (physiotherapy limited to hospital stay, 20 min on 5 days per week)
Number of subjects: 56
Study: 35921262

Group type: EXPERIMENTAL
Intervention: Perceived choice in music (intervention group)
Number of subjects: 286

Group type: COMPARATOR
Intervention: No choice in music (control group)
Number of subjects: 286

Group type: EXPERIMENTAL
Intervention: High complexity music (intervention group)
Number of subjects: 286

Group type: COMPARATOR
Intervention: Low complexity music (control group)
Number of subjects: 286
Study: 33023589

Group type: EXPERIMENTAL
Intervention: Outreach case management for 12 months
Number of subjects: 60
Study: 35064715

Group type: EXPERIMENTAL
Intervention: Community-based multi-month dispensing (MMD) of antiretroviral treatment (ART) with options for 3-monthly or 6-monthly dispensing.
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Community-based multi-month dispensing (MMD) of ART
Number of subjects: 20
Study: 33957389

Group type: COMPARATOR
Intervention: Vinpocetine 10 mg oral
Number of subjects: 16

Group type: COMPARATOR
Intervention: Vinpocetine 20 mg oral
Number of subjects: 16

Group type: COMPARATOR
Intervention: Vinpocetine 60 mg oral
Number of subjects: 16

Group type: COMPARATOR
Intervention: Vinpocetine 20 mg oral three times a day (one-month open label)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 36079139

Group type: EXPERIMENTAL
Intervention: Active tDCS (n = 60)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Sham tDCS (n = 60)
Number of subjects: 120
Study: 35187731

Group type: COMPARATOR
Intervention: Guided Bone Regeneration (GBR)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Connective Tissue Graft (CTG)
Number of subjects: 42
Study: 33136159

Group type: EXPERIMENTAL
Intervention: Caspofungin
Number of subjects: 290

Group type: COMPARATOR
Intervention: Triazole (Fluconazole)
Number of subjects: 290

Group type: COMPARATOR
Intervention: Triazole (Voriconazole)
Number of subjects: 290
Study: 32403130

Group type: EXPERIMENTAL
Intervention: 12-week intensive intervention comprising lifestyle approaches and treatment with insulin glargine, metformin, and dapagliflozin
Number of subjects: 154

Group type: COMPARATOR
Intervention: Standard diabetes care
Number of subjects: 154
Study: 35441559

Group type: EXPERIMENTAL
Intervention: US transducer-guided radial artery puncture technology with guide marks on the side of the US transducer probe
Number of subjects: 127

Group type: COMPARATOR
Intervention: Conventional US transducer-guided radial artery puncture technology
Number of subjects: 127
Study: 32146619

Group type: EXPERIMENTAL
Intervention: Telotristat ethyl 250 mg tid
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Telotristat ethyl 500 mg tid
Number of subjects: 69
Study: 32680487

Group type: EXPERIMENTAL
Intervention: Fast-track pathway for MRI scan and spinal specialist opinion
Number of subjects: 40
Study: 33663316

Group type: EXPERIMENTAL
Intervention: Dapoxetine taste-masked oral thin films (OTFs) with pullulan, glycerol, AmberLite, and dapoxetine (30 mg)
Number of subjects: 0
Study: 616870332

Group type: EXPERIMENTAL
Intervention: Everolimus
Number of subjects: 562

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 562

Group type: EXPERIMENTAL
Intervention: Everolimus with concomitant octreotide
Number of subjects: 562
Study: 36381457

Group type: EXPERIMENTAL
Intervention: Half-saline (HS) irrigation solution
Number of subjects: 61

Group type: COMPARATOR
Intervention: Normal-saline (NS) irrigation solution
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Half-saline (HS) and Normal-saline (NS)
Number of subjects: 61
Study: 33257672

Group type: EXPERIMENTAL
Intervention: FLOT regimen (4 cycles of docetaxel, oxaliplatin, fluorouracil, and leucovorin)
Number of subjects: 74

Group type: COMPARATOR
Intervention: SOX regimen (3 cycles of tegafur gimeracil oteracil potassium capsule plus oxaliplatin)
Number of subjects: 74
Study: 36469329

Group type: EXPERIMENTAL
Intervention: Full remediation (installing working windows and doors, cleaning trash, weeding)
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Trash cleanup and weeding only
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Housing remediation or trash cleanup treatment
Number of subjects: 301

Group type: COMPARATOR
Intervention: No-intervention control
Number of subjects: 301
Study: 33961292

Group type: EXPERIMENTAL
Intervention: Low-dose cytosine arabinoside (LDAC) plus tosedostat (LDAC-T)
Number of subjects: 243

Group type: COMPARATOR
Intervention: Low-dose cytosine arabinoside (LDAC)
Number of subjects: 243
Study: 32965235

Group type: EXPERIMENTAL
Intervention: everyBody Plus web-based cognitive behavioral intervention
Number of subjects: 116
Study: 33622544

Group type: EXPERIMENTAL
Intervention: Cast clasps in a 0.25-mm undercut
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Wrought round wire of 1-mm diameter
Number of subjects: 60
Study: 34213773

Group type: EXPERIMENTAL
Intervention: Tri-layer nitrile-latex gloves
Number of subjects: 46

Group type: COMPARATOR
Intervention: Natural rubber latex gloves
Number of subjects: 46

Group type: COMPARATOR
Intervention: Unused gloves
Number of subjects: 46
Study: 34942105

Group type: EXPERIMENTAL
Intervention: Atropine 0.05%
Number of subjects: 314

Group type: EXPERIMENTAL
Intervention: Atropine 0.025%
Number of subjects: 314

Group type: EXPERIMENTAL
Intervention: Atropine 0.01%
Number of subjects: 314
Study: 33996039

Group type: EXPERIMENTAL
Intervention: Interviewer-administered seven-day semi-quantitative food frequency questionnaire (7-d SQFFQ)
Number of subjects: 105
Study: 32321570

Group type: EXPERIMENTAL
Intervention: Extended-release naltrexone (XR-NTX) before release
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Enhanced XR-NTX (mobile medical treatment post-release)
Number of subjects: 0

Group type: COMPARATOR
Intervention: XR-NTX (standard referral to community treatment program post-release)
Number of subjects: 0
Study: 34739763

Group type: EXPERIMENTAL
Intervention: Mean Arterial Pressure (MAP)
Number of subjects: 3428

Group type: EXPERIMENTAL
Intervention: Pulse Pressure
Number of subjects: 3428

Group type: COMPARATOR
Intervention: MAP and Pulse Pressure (both groups)
Number of subjects: 3428
Study: 32947547

Group type: EXPERIMENTAL
Intervention: Optimized acupuncture
Number of subjects: 896

Group type: COMPARATOR
Intervention: Shallow acupuncture
Number of subjects: 896

Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 896
Study: 32507439

Group type: EXPERIMENTAL
Intervention: Garlic powder supplementation (400 mg per tablet, 4 tablets daily for 12 weeks)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo (400 mg starch per tablet, 4 tablets daily for 12 weeks)
Number of subjects: 90
Study: 34344230

Group type: EXPERIMENTAL
Intervention: Low-intensity aerobic training
Number of subjects: 76

Group type: COMPARATOR
Intervention: High-intensity aerobic training
Number of subjects: 76
Study: 34323454

Group type: EXPERIMENTAL
Intervention: Sphenopalatine ganglion block (SPGB) in treatment group A
Number of subjects: 123

Group type: COMPARATOR
Intervention: Control group B (no PDPH)
Number of subjects: 123
Study: 32487971

Group type: EXPERIMENTAL
Intervention: Trunk stability exercise wearing a pelvic belt on the paretic side
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Trunk stability exercise wearing a pelvic belt on the nonparetic side
Number of subjects: 36

Group type: COMPARATOR
Intervention: Trunk stability exercise without a pelvic belt (control group)
Number of subjects: 36
Study: 34737187

Group type: EXPERIMENTAL
Intervention: Liraglutide (1.8 mg daily for 5 weeks after 2 weeks of titration)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study: 33621253

Group type: EXPERIMENTAL
Intervention: Ipratropium bromide + salbutamol
Number of subjects: 6396

Group type: COMPARATOR
Intervention: Salbutamol alone
Number of subjects: 6396
Study: 33856948

Group type: EXPERIMENTAL
Intervention: Wire Localization (WL)
Number of subjects: 631

Group type: EXPERIMENTAL
Intervention: Radioactive Seed (RS)
Number of subjects: 631

Group type: EXPERIMENTAL
Intervention: Savi Scout (SS)
Number of subjects: 631
Study: 33382406

Group type: EXPERIMENTAL
Intervention: START-Play intervention plus usual care early intervention (UC-EI)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Usual care early intervention (UC-EI)
Number of subjects: 112
Study: 34016825

Group type: EXPERIMENTAL
Intervention: Centrifuged adipose tissue injection
Number of subjects: 116

Group type: COMPARATOR
Intervention: No injection of centrifuged adipose tissue (control)
Number of subjects: 116
Study: 34521135

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided continuous thoracic paravertebral block (UG-TPVB)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Conventional patient-controlled analgesia (PCA)
Number of subjects: 128
Study: 35085839

Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control
Number of subjects: 40
Study: 33196797

Group type: EXPERIMENTAL
Intervention: BMI reporting (group 1)
Number of subjects: 28641

Group type: EXPERIMENTAL
Intervention: BMI screening only (group 2)
Number of subjects: 28641

Group type: COMPARATOR
Intervention: Control (group 3)
Number of subjects: 28641
Study: 32404059

Group type: EXPERIMENTAL
Intervention: Community-based intervention (up to three in-home visits, monthly group wellness program, monthly case conferencing, care coordination)
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Community-based intervention
Number of subjects: 132

Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 132
Study: 35049029

Group type: EXPERIMENTAL
Intervention: Mindful parenting training (8 sessions of 90 minutes each)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 24
Study: 34915884

Group type: EXPERIMENTAL
Intervention: 8-item Altarum Consumer Engagement Measure™ (ACE Measure) - Commitment subscale
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: 8-item Altarum Consumer Engagement Measure™ (ACE Measure) - Navigation subscale
Number of subjects: 400
Study: 33232714

Group type: EXPERIMENTAL
Intervention: Fat graft
Number of subjects: 24

Group type: COMPARATOR
Intervention: Gelatin sponge
Number of subjects: 24
Study: 34559090

Group type: EXPERIMENTAL
Intervention: Memantine 10 mg daily for 10 days, then 20 mg daily for 21 days
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (same shape and size as memantine tablets)
Number of subjects: 60
Study: 32491932

Group type: EXPERIMENTAL
Intervention: Cabozantinib in combination with atezolizumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sorafenib
Number of subjects: 0
Study: 36251140

Group type: EXPERIMENTAL
Intervention: Naoxintong Capsule (1.2 g orally, twice a day)
Number of subjects: 2200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2200
Study: 34174848

Group type: EXPERIMENTAL
Intervention: MYL‐1501D
Number of subjects: 1118

Group type: COMPARATOR
Intervention: Reference insulin glargine
Number of subjects: 1118
Study: 35538185

Group type: EXPERIMENTAL
Intervention: Tanezumab 2.5 mg
Number of subjects: 306

Group type: EXPERIMENTAL
Intervention: Tanezumab 5 mg
Number of subjects: 306

Group type: COMPARATOR
Intervention: NSAID
Number of subjects: 306

Group type: EXPERIMENTAL
Intervention: Tanezumab
Number of subjects: 306

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 306
Study: 33420602

Group type: EXPERIMENTAL
Intervention: Valerian extract (530 mg for 30 nights)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo (530 mg for 30 nights)
Number of subjects: 72
Study: 34029279

Group type: EXPERIMENTAL
Intervention: Patient-friendly reports
Number of subjects: 300

Group type: COMPARATOR
Intervention: Traditional reports
Number of subjects: 300
Study: 32267059

Group type: EXPERIMENTAL
Intervention: Endobronchial coils treatment
Number of subjects: 78
Study: 34420884

Group type: EXPERIMENTAL
Intervention: Percutaneous cholecystostomy tube (PCT)
Number of subjects: 13283

Group type: COMPARATOR
Intervention: Cholecystectomy
Number of subjects: 13283

Group type: EXPERIMENTAL
Intervention: Decompensated cirrhosis
Number of subjects: 13283

Group type: EXPERIMENTAL
Intervention: Cirrhosis (compensated and decompensated)
Number of subjects: 13283
Study: 34326642

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Fluoxetine + CBT
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Fluoxetine + Bupropion
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Fluoxetine + Bupropion + Brain Stimulation
Number of subjects: 113

Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 113
Study: 32896498

Group type: EXPERIMENTAL
Intervention: Anti-VEGF therapy
Number of subjects: 24
Study: 32443981

Group type: EXPERIMENTAL
Intervention: Cognitive Rehabilitation (CR) plus Aerobic Exercise (EX)
Number of subjects: 360

Group type: COMPARATOR
Intervention: Cognitive Rehabilitation (CR) plus Sham Exercise
Number of subjects: 360

Group type: COMPARATOR
Intervention: Cognitive Rehabilitation Sham plus Aerobic Exercise (EX)
Number of subjects: 360

Group type: COMPARATOR
Intervention: Cognitive Rehabilitation Sham plus Sham Exercise
Number of subjects: 360
Study: 33954859

Group type: COMPARATOR
Intervention: 0.01% atropine (SA group)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Orthokeratology (OK group)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Combination of orthokeratology and 0.01% atropine (OKA group)
Number of subjects: 67
Study: 32526153

Group type: EXPERIMENTAL
Intervention: Ankle trainer device
Number of subjects: 113

Group type: COMPARATOR
Intervention: Conventional physiotherapy
Number of subjects: 113
Study: 34213808

Group type: EXPERIMENTAL
Intervention: Fractional CO2 laser
Number of subjects: 19

Group type: COMPARATOR
Intervention: Full ablative CO2 laser
Number of subjects: 19
Study: 33775558

Group type: EXPERIMENTAL
Intervention: Durvalumab
Number of subjects: 488

Group type: EXPERIMENTAL
Intervention: Durvalumab + Tremelimumab
Number of subjects: 488
Study: 35120719

Group type: EXPERIMENTAL
Intervention: Assessment by an experienced geriatric nurse and proposal of a care plan
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care (simple information on ageing well and on the prevention of falls at home)
Number of subjects: 0
Study: 32353536

Group type: EXPERIMENTAL
Intervention: Spectral-Domain OCT (SD OCT)
Number of subjects: 1094

Group type: COMPARATOR
Intervention: Fluorescein Angiography (FFA)
Number of subjects: 1094
Study: 35918097

Group type: EXPERIMENTAL
Intervention: Drug treatment
Number of subjects: 73388

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73388
Study: 32756204

Group type: EXPERIMENTAL
Intervention: Nasal high-flow (NHF) therapy with room air only and no supplemental oxygen
Number of subjects: 0

Group type: COMPARATOR
Intervention: No respiratory support
Number of subjects: 0

Group type: COMPARATOR
Intervention: Face mask oxygen administration
Number of subjects: 0

Group type: COMPARATOR
Intervention: Spontaneous breathing without performing respiratory support
Number of subjects: 0
Study: 33788453

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) at Neimadian-point plus analgesia pump (normal saline)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Sufentanil patient-controlled intravenous analgesia plus sham EA (without stimulation)
Number of subjects: 140
Study: 36345847

Group type: EXPERIMENTAL
Intervention: Rehearsal expressive writing
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Replay expressive writing
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: All groups measured for psychological adjustment (MHI), self-perceived stress, depression and anxiety symptoms, and self-blame
Number of subjects: 100
Study: 32173050

Group type: EXPERIMENTAL
Intervention: Decision aid showing benefits and harms of screening
Number of subjects: 400

Group type: COMPARATOR
Intervention: Standard brochure recommending participation in screening
Number of subjects: 400
Study: 33079803

Group type: EXPERIMENTAL
Intervention: 5 S's infant calming technique
Number of subjects: 250

Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 250
Study: 35358455

Group type: EXPERIMENTAL
Intervention: Anetumab ravtansine (6.5 mg/kg on day 1 of each 21-day cycle)
Number of subjects: 248

Group type: COMPARATOR
Intervention: Vinorelbine (30 mg/m2 once every week)
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: Anetumab ravtansine
Number of subjects: 248

Group type: COMPARATOR
Intervention: Vinorelbine
Number of subjects: 248
Study: 33637926

Group type: EXPERIMENTAL
Intervention: Scale and Polish (S&P) 6-monthly
Number of subjects: 1327

Group type: EXPERIMENTAL
Intervention: Scale and Polish (S&P) 12-monthly
Number of subjects: 1327

Group type: EXPERIMENTAL
Intervention: Personalised Oral Hygiene Advice (OHA)
Number of subjects: 1327

Group type: COMPARATOR
Intervention: Usual Oral Hygiene Advice (OHA)
Number of subjects: 1327
Study: 32026250

Group type: EXPERIMENTAL
Intervention: Short intervention discussing violence and power with women receiving HIV testing services; included training and support for HIV counselors, a take-home card for clients, and an on-site IPV counselor.
Number of subjects: 688
Study: 36103212

Group type: EXPERIMENTAL
Intervention: High dosing grape seed flour (GSF ≈ 1 g/kg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Starch (placebo)
Number of subjects: 40
Study: 34015024

Group type: EXPERIMENTAL
Intervention: Difficult working conditions
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Reinforcing factors
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Perceived risks
Number of subjects: 25
Study: 32191729

Group type: EXPERIMENTAL
Intervention: Customized CarePlus Wrap
Number of subjects: 301

Group type: COMPARATOR
Intervention: Traditional chitenje
Number of subjects: 301
Study: 35904063

Group type: EXPERIMENTAL
Intervention: Oral carvedilol 5 mg bid (twice per day)
Number of subjects: 156

Group type: COMPARATOR
Intervention: Topical brimonidine
Number of subjects: 156
Study: 34297363

Group type: EXPERIMENTAL
Intervention: Prebiotic inulin‐type fructans (ITF) 16 g/d
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control supplement (maltodextrin) 16 g/d
Number of subjects: 29
Study: 32684359

Group type: EXPERIMENTAL
Intervention: Mailed motivational messaging screening reminder letter with an option to call and request a free at-home fecal immunochemical screening test
Number of subjects: 7812

Group type: COMPARATOR
Intervention: Standard invitation letter detailing that the individual was due for screening (control)
Number of subjects: 7812

Group type: EXPERIMENTAL
Intervention: Mailed motivational messaging screening reminder letter
Number of subjects: 7812

Group type: EXPERIMENTAL
Intervention: Fecal immunochemical test kits mailed to participants
Number of subjects: 7812
Study: 35277023

Group type: EXPERIMENTAL
Intervention: Continuous enteral feeding
Number of subjects: 99

Group type: COMPARATOR
Intervention: Intermittent enteral feeding
Number of subjects: 99
Study: 32910077

Group type: EXPERIMENTAL
Intervention: Pessary use for more than 1 year
Number of subjects: 132
Study: 32562889

Group type: EXPERIMENTAL
Intervention: Baveno VI criteria (B6C)
Number of subjects: 2368

Group type: EXPERIMENTAL
Intervention: ANTICIPATE score
Number of subjects: 2368

Group type: EXPERIMENTAL
Intervention: VariScreen
Number of subjects: 2368

Group type: EXPERIMENTAL
Intervention: Expanded Baveno VI criteria (EB6C)
Number of subjects: 2368

Group type: EXPERIMENTAL
Intervention: Overall strategy
Number of subjects: 2368
Study: 33132094

Group type: EXPERIMENTAL
Intervention: Fitmore stem implantation in female patients
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Fitmore stem implantation in male patients
Number of subjects: 57